Drug Trial Radar · NCT07051538
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Jun 26, 2024
Primary completion
Nov 28, 2025
Study completion Nov 28, 2025
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of SHR-1139 injection, and in patients with moderate - to - severe plaque psoriasis who receive multiple subcutaneous injections of SHR-1139 injection.
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
SHR-1139 InjectionsDrug
SHR-1139 injections.
SHR-1139 Injections PlaceboDrug
SHR-1139 injections placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: About 365 days for moderate-to-severe plaque psoriasis subjects
- Adverse events (AEs)Time frame: About 295 days for healthy subjects.
- Serious adverse events (SAEs)Time frame: About 295 days for healthy subjects.
- Serious adverse events (SAEs)Time frame: About 365 days for moderate-to-severe plaque psoriasis subjects.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.